Conéctate
Conéctate
O Conectarse con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Regístrate
O Conectarse con
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BEIGENE, LTD.

(BGNE)
  Reporte
Diferido Nasdaq  -  22:00 30/09/2022
134.82 USD   -1.07%
27/09Los ADRs asiáticos suben en las operaciones del martes
MT
27/09BeiGene registra pérdidas netas de 1.000 millones de dólares en el primer semestre
MT
20/09Inglaterra aprueba el medicamento de BeiGene para el linfoma
MT
ResumenCotizacionesGráficosNoticiasRatingsAgendaEmpresaFinanzasConsensoRevisionesDerivadosFondos 
ResumenTodasRecomendaciones analistasOtros idiomasComunicadosPubls. oficialesNoticias del sectorEstrategias MarketScreener
Noticias en otros idiomas sobre BEIGENE, LTD.
27/09Asian ADRs Move Higher in Tuesday Trading
27/09BeiGene Posts $1.0 Billion in Net Losses For H1
22/09Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
20/09NICE Recommends BeiGene's BRUKINSA for Patients with Waldenstrom's Macroglobulinemia wh..
20/09BeiGene Receives Positive CHMP Opinion for BRUKINSA for the Treatment of Adults with Ma..
20/09BeiGene Says UK's National Institute for Health and Care Excellence Backs Approval of L..
20/09England Approves BeiGene's Lymphoma Medication
20/09U.K. National Institute for Health and Care Excellence Approves BeiGene's BRUKINSA As R..
20/09Chinese Biotech BeiGene's Blood Cancer Therapy Wins Recommendations in EU, UK
20/09NICE Recommends BeiGene's BRUKINSA® (zanubrutinib) for Patients with Waldenström's Macr..
20/09NICE Recommends Beigene’s BRUKINSA® (Zanubrutinib) for Patients with Waldenström&#..
19/09BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment o..
19/09BeiGene, Ltd.Receives Positive Committee for Medicinal Products for Human Use Opinion f..
19/09BeiGene's Brukinsa Drug Recommended for EU Authorization
15/09Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
14/09Transcript : BeiGene, Ltd. Presents at Morgan Stanley 20th Annual Global Heal..
14/09Beigene, Ltd. Announces Appointment of Member of Compensation Committee
13/09BeiGene's Hepatocellular Carcinoma Study Reaches Primary Endpoint
10/09Novartis: succès relatif d'un programme contre le cancer du foie
10/09Novartis: Leberkrebs-Behandlung Tislelizumab ist Sorafenib nicht unterlegen
10/09BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presenta..
10/09BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presenta..
08/09BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
06/09China-focused hedge funds lower exposure as risks mount
06/09China-focused hedge funds lower exposure as risks mount
31/08BeiGene Books Wider Loss in H1 as Revenue Plunges 14%
29/08Asian ADRs Move Slightly Higher in Monday Trading
29/08US, China Reach Audit Deal to Prevent Delistings
25/08Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
23/08BeiGene Says China Regulators Accept sBLA for Tislelizumab Combined With Chemotherapy i..
23/08BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizu..
23/08BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizu..
18/08Asian ADRs Move Lower in Thursday Trading
15/08BeiGene, McKesson Unit to Collaborate to Improve Patient Access to Cancer Drugs
15/08BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Car..
15/08BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Car..
10/08Beigene : Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab ..
10/08Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
10/08Asian ADRs Move Sharply Higher in Wednesday Trading
09/08Novartis-BeiGene Liver Cancer Drug Works As Well As Bayer's Nexavar in Phase 3 Study
09/08Novartis : résultats positifs dans le cancer du foie
09/08BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab..
09/08BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab..
08/08BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
05/08Another case of good news is bad news
05/08Analyst recommendations: Eli Lilly, KLA, Kellogg, Epam Systems, ..
05/08BeiGene Shares Gain After Doubling of Second-Quarter Revenue
04/08BeiGene Q2 Net Loss per ADS Widens as Revenue Rises; Shares Surge
04/08Beigene : Reports Second Quarter 2022 Financial Results - Form 8-K
04/08Earnings Flash (BGNE) BEIGENE Posts Q2 Revenue $341.6M
04/08Beigene, Ltd. : Results of Operations and Financial Condition, Other Events, Financial Sta..
04/08BeiGene Reports Second Quarter 2022 Financial Results
04/08BeiGene, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June..
28/07SEC Chair Stresses Need to Reach Audit Deal With Chinese Regulators
26/07China’s Securities Watchdog Denies Plan to Help Firms Avoid US Delisting
20/07Beigene, Ltd. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
20/07Deal to Avoid Delisting of 200 Firms in US Bourses Remains Unclear
15/07Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
15/07Beigene : Provides Regulatory Update on the U.S. Biologics License Application (BLA) for P..
15/07US FDA Delays Action On Novartis Partner's Biologics License Application For Tislelizum..
14/07Sector Update: Health Care Stocks Unable to Climb Back to Positive Ground
14/07Sector Update: Health Care Stocks Declining Thursday with Broader Markets
14/07Novartis: l'homologation du tislelizumab aux USA prend du retard
14/07Novartis-Partner Beigene berichtet über Zulassungsverzögerung für Tislelizumab
14/07BeiGene Says US FDA Defers Action on Biologics License Application for Tislelizumab
14/07BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for ..
14/07Beigene Provides Regulatory Update on the U.S. Biologics License Application for Pd 1 I..
14/07Beigene Says FDA Defers Action on BLA Due to Covid Travel Restrictions
13/07Asian ADRs Move Lower in Wednesday Trading
13/07BeiGene Appoints Chan Lee as General Counsel
13/07BeiGene, Ltd. Appoints Chan Lee as General Counsel, July 18 2022
12/07Leap Therapeutics, BeiGene Initiate New DKN-01 Trials for Cancers
12/07Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials ..
06/07BeiGene Shares Drop 12% After Deal to License InnoRNA Technology
06/07Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
06/07BeiGene, InnoRNA Enter Into mRNA Research Collaboration
06/07BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Nov..
06/07BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Nov..
05/07Asian ADRs Fall Sharply in Tuesday Trading
30/06Beigene : Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tis..
30/06Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
30/06Novartis livre des indications sur le tislélizumab en oncologie
30/06BeiGene Says Esophageal Cancer Combination Therapy Improved Overall Survival in Phase 3..
30/06Novartis-Mittel Tislelizumab lässt Speiseröhrenkrebs-Patienten länger leben
30/06BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti..
30/06BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Ti..
27/06BeiGene Grants Share Options, Restricted Share Units
27/06Antengene Corporation Limited Announces Clinical Trial Collaboration with BeiGene, Ltd...
24/06Asian ADRs Climb Higher in Friday Trading
23/06Beigene : Announces Acceptance of Supplemental Biologics License Application in China for ..
22/06Insider Sell: Beigene
22/06Insider Sell: Beigene
22/06Beigene, Ltd. : Change in Directors or Principal Officers, Submission of Matters to a Vote..
22/06Beigene, Ltd. Announces Executive Changes
21/06European ADRs Rise Sharply in Tuesday Trading
21/06Sector Update: Health Care Stocks Edge Higher Premarket Tuesday
21/06BeiGene Says China Regulators Accept Supplemental Biologics License Application for Ant..
21/06BeiGene Announces Acceptance of Supplemental Biologics License Application in China for..
21/06Beigene Announces Acceptance of Supplemental Biologics License Application in China for..
15/06Certain Options of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-JUN-20..